A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...

The researchers suggest clinicians might tailor their approach to account for Asian Americans' younger average age when they ...

John Dowd April is National Volunteer Month, and the Bitterroot is not short of volunteers that go above and beyond for the community. However, given that last month was […] ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosisResults from the HERCULES phase 3 ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Researchers from the Netherlands Institute for Neuroscience (NIN) have discovered new potential therapeutic targets for ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of ...

An American neurologist and an Italian epidemiologist whose work revolutionized the treatment of multiple sclerosis on Saturday won a prestigious Breakthrough Prize, the award nicknamed the “Oscars of ...

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed.

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...